Neuromuscular blockers in surgery and intensive care, part 2

American Journal of Health-System Pharmacy

Volumn 58, Issue 24, 2001, Pages 2381-2395

  McManus, M C ^a  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Critical illness; Drug interactions; Mechanism of action; Pharmacodynamics; Pharmacokinetics; Skeletal muscle relaxants; Surgery; Toxicity

Indexed keywords

ACETYLCHOLINE; ANTIINFECTIVE AGENT; ATRACURIUM BESILATE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CISATRACURIUM; DIMETHYLTUBOCURARINE CHLORIDE; DOXACURIUM; INHALATION ANESTHETIC AGENT; MIVACURIUM; NEUROMUSCULAR BLOCKING AGENT; NICOTINIC RECEPTOR; PANCURONIUM BROMIDE; PIPECURONIUM BROMIDE; RAPACURONIUM BROMIDE; ROCURONIUM; SUXAMETHONIUM; TUBOCURARINE CHLORIDE; VECURONIUM;

ACETYLCHOLINE RELEASE; CROSS REACTION; DRUG COST; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; ENZYME INHIBITION; HUMAN; HYPOKALEMIA; INTENSIVE CARE; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; NEUROTRANSMISSION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SURGERY;

EID: 0035893585     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.24.2381     Document Type: Review

References (131)

1. Clinical uses and controversies of neuromuscular blocking agents in infants and children
2. Dose-response curves for succinylcholine: Single versus cumulative techniques
3. Effect of d-tubocurarine pretreatment on succinylcholine twitch augmentation and neuromuscular blockade
4. Comparison of rocuronium and mivacurium to succinylcholine during outpatient laparoscopic surgery
5. Comparison of high and low doses of suxamethonium
6. Succinylcholine: A new approach to muscular relaxation in anesthesiology
7. Muscle relaxants
8. The use of neuromuscular blocking agents in the ICU
9. Pharmacology of neuromuscular blocking agents in the intensive care unit
10. Agents at the neuromuscular junction and autonomic ganglia
11. Use of muscle relaxants in the intensive care unit
12. Neuromuscular relaxants: Complications
13. Cholinesterase and succinylcholine
14. Long-term succinylcholine infusion during isoflurane anesthesia
15. Clinical pharmacology of neuromuscular blocking agents
16. Muscle relaxants
17. The effects of succinylcholine on mouth opening
18. Dose-related effects of succinylcholine on the adductor pollicis and masseter muscles in children
19. Implications of masseter spasm after succinylcholine
20. Recent advances in pediatric anesthesia
21. Suxamethonium - A review
22. Neuromuscular blockade in the emergency department
23. Suxamethonium
24. Routine suxamethonium in children. A regional survey of current usage
25. The heart rate response to succinylcholine in children: A comparison of atropine and glycopyrrolate
26. Controversies in muscle relaxants
27. Prevention of succinylcholine myalgias. A meta-analysis
28. Dantrolene and suxamethonium: Myalgia, biochemical changes and serum dantrolene levels following oral dantrolene pre-treatment in laparoscopy patients
29. Hyperkalemia and cardiovascular collapse following administration of succinylcholine to the traumatized patient
30. The serum potassium response to muscle relaxants in neural injury
31. Neuromuscular blocking drugs
32. Succinylcholine-induced hyperkalemia in patients with ruptured cerebral aneurysms
33. Serum potassium changes after succinylcholine in patients with acute massive muscle trauma
34. Cardiac arrest after succinylcholine administration in a pregnant patient recovered from Guillain-Barre syndrome
35. Succinylcholine-induced hyperkalemic arrest in a patient with severe metabolic acidosis and exsanguinating hemorrhage
36. Suxamethonium is contraindicated in the Guillain-Barre syndrome
37. Suxamethonium-induced cardiac arrest and death following 5 days of immobilization
38. Gastroesophageal pressure gradient changes produced by induction of anaesthesia and suxamethonium
39. Pharmacology of anesthetics
40. The effect of suxamethonium on intraocular pressure
41. Time course of action and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant; a comparison with succinylcholine
42. Evaluation of neuromuscular and cardiovascular effects of two doses of rapacuronium (ORG 9487) versus mivacurium and succinylcholine
43. A comparison of cisatracurium and atracurium: Onset of neuromuscular block after bolus injection and recovery after subsequent infusion
44. Rapacuronium bromide
45. Dose-ranging study in younger adult and elderly patients of ORG 9487, a new, rapidonset, short-duration muscle relaxant
46. A large simple randomized trial of rocuronium versus succinylcholine in rapidsequence induction of anaesthesia along with propofol
47. Comparison of intubating conditions after rapacuronium (Org 9487) and succinylcholine following rapid sequence induction in adult patients
48. Rapidsequence orotracheal intubation with rocuronium: A randomized double-blind comparison with suxamethonium - Preliminary communication
49. Rocuronium - Onset times and intubating conditions
50. Pain on injection of rocuronium bromide
51. Pain on injection of rocuronium
52. The changing pharmacodynamics of metocurine identify the onset and offset of canine gastrocnemius disuse atrophy
53. Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine
54. Pancuronium infusion for neuromuscular block in children in the pediatric intensive care unit
55. Long-term administration of pancuronium and pipecuronium in the intensive care unit
56. Synaptic structure and development: The neuromuscular junction
57. Early reversal of rapacuronium with neostigmine
58. Vecuronium neuromuscular blockade at the diaphragm, the orbicularis ocuti and adductor pollicis muscles
59. Admissions to the intensive care unit after complications of anaesthetic techniques over 10 years. 1. The first 5 years
60. Complications associated with anaesthesia - A prospective survey in France
61. Milliamperage requirements for supramaximal stimulation of the ulnar nerve with surface electrodes
62. Peripheral nerve stimulation performance: The influence of output polarity and electrode placement
63. Clinical use nerve stimulators in anaesthesia
64. Monitoring and reversal of neuromuscular blockade
65. The relation between the response to "train-of-four" stimulation and receptor occlusion daring competitive neuromuscular block
66. The margin of safety of neuromuscular transmission in the muscle of the diaphragm
67. Neuromuscular blockage: Measurement and monitoring
68. Tactile and visual evaluation of the response to train-of-four nerve stimulation
69. Clinical evaluation of double-burst stimulation. Its relationship to train-of-four stimulation
70. Manual evaluation of residual curarization using double burst stimulation: A comparison with train-of-four
71. Fade of neurally evoked compound electromyogram during neuromuscular block by d-tubocurarine
72. Monitoring and preventive care of the paralyzed patient in respiratory failure
73. Technical and interpretive problems of peripheral nerve stimulation in monitoring neuromuscular blockade in the intensive care unit
74. Persistent paralysis in critically ill patients after the use of neuromuscular blocking agents in critical care
75. Acute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and vecuronium
76. Assessment of recovery from curare
77. Nondepolarizing neuromuscular blocking drugs in the intensive care unit: A clinical review
78. The effect of tubocurarine on indirectly elicited train-of-four muscle response and respiratory measurements in humans
79. New neuromuscular blocking drugs
80. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers
81. Quantitative assessment of residual antidepolarizing block. I
82. Neurotransmission. The autonomic and somatic motor nervous systems
83. The margin of safety of neuromuscular transmission
84. Use of neuromuscular blocking medications in critically ill patients
85. Residual curarization in the recovery room
86. Partial curarization in the postoperative period
87. Postoperative neuromuscular blockade: A comparison between atracurium, vecuronium and pancuronium
88. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium
89. Anaesthesia-related surgical mortality
90. Postoperative neuromuscular block following atracurium or alcuronium in children
91. The impact of choice of muscle relaxant on postoperative recovery time: A retrospective study
92. Attenuated ventitatory response to hypoxaemia after vecuronium-induced neuromuscular block
93. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans
94. Neostigmine and edrophonium antagonism of varying intensity neuromuscular blockade induced by atracurium, pancuronium, or vecuronium
95. Neostigmine, pyridostigmine and edrophonium as antagonists of deep pancuronium block
96. A clinical evaluation of pyridostigmine bromide in the reversal of curarization
97. Dose-response relationships for edrophonium and neostigmine antagonism of pipecuroniuminduced neuromuscular block
98. Antagonism of vecuronium-induced neuromuscular blockade with edrophonium or neostigmine
99. Clinical pharmacology of rapacuronium bromide, a new short-acting neuromuscular blocking agent
100. Edrophonium: Duration of action and atropine requirement in humans during halothane anesthesia
101. The potencies of edrophonium and neostigmine as antagonists of pancuronium
102. Dose-response curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine
103. Dose-response relationships for edrophonium and neostigmine as antagonists of moderate and profound atracurium blockade
104. Doseresponse relationships for edrophonium and neostigmine as antagonists of atracurium and vecuronium neuromuscular blockade
105. Antagonism of atracurium with neostigmine. Effect of dose on speed of recovery
106. Is recovery of neuromuscular transmission complete after the use of neostigmine to antagonize block produced by rocuronium, vecuronium, atracurium and pancuronium?
107. Neostigmine, pyridostigmine, and edrophonium as antagonists of pancuronium
108. Comparative times to peak effect and duration of action of neostigmine and pyridostigmine
109. Neostigmine after spontaneous recovery from neuromuscular blockade. Effect on depth of blockade monitored with train-of-four and tetanic stimuli
110. Electrical and mechanical responses after neuromuscular blockade with vecuronium, and subsequent antagonism with neostigmine or edrophonium
111. Neuromuscular blockade by neostigmine in anaesthetized man
112. Dose-response relationships for edrophonium and neostigmine antagonism of rocuronium bromide (ORG 9426)-induced neuromuscular blockade
113. The reversal of profound mivacurium-induced neuromuscular blockade
114. Neostigmine and edrophonium as antagonists of pancuronium in infants and children
115. The neuromuscular pharmacology of neostigmine in infants and children
116. Effect of hypocarbia and hypercarbia on the antagonism of pancuronium-induced neuromuscular blockade with neostigmine in man
117. Edrophonium antagonism of atracurium during enflurane anaesthesia
118. Antagonism of pancuronium in renal failure: No recurarization
119. Antagonism of neuromuscular block in the elderly. A comparison of atropine and glycopyrronium in a mixture with neostigmine
120. Comparison of glycopyrrolate, atropine and hyoscine in mixture with neostigmine for reversal of neuromuscular block following closed mitral valvotomy
121. Effects of four anticholinesterase-anticholinergic combinations and tracheal extubation on QTc interval of the ECG, heart rate and arterial pressure
122. The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period
123. Anaesthesia and bowel surgery
124. Influence of neostigmine on postoperative vomiting